The Efficacy of Cinacalcet in the Treatment of Hyperparathyroidism in Turkish Hemodialysis Patient Population

Basit Öğe Kaydı
dc.authoridTurkmen, Kultigin/0000-0002-1667-7716
dc.authoridhur, ender/0000-0002-8066-4629
dc.authoridKOSE, SENNUR/0000-0002-1920-5159
dc.authoridBakirdogen, Serkan/0000-0002-3448-0490
dc.authoridkaya, bulent/0000-0003-4697-4815
dc.authoridUlutas, Ozkan/0000-0002-2155-8340
dc.authoridAri, Elif/0000-0001-9208-7972
dc.contributor.authorAltunoren, Orcun
dc.contributor.authorGungor, Ozkan
dc.contributor.authorEren, Necmi
dc.contributor.authorTanrisev, Mehmet
dc.contributor.authorHur, Ender
dc.contributor.authorTurkmen, Kultigin
dc.contributor.authorYavuz, Yasemin Coskun
dc.date.accessioned2024-09-18T20:11:27Z
dc.date.available2024-09-18T20:11:27Z
dc.date.issued2016
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractOBJECTIVE: Cinacalcet reduces parathyroid hormone levels by increasing the sensitivity of the parathyroid gland to calcium. In this study, we firstly aimed to evaluate the efficacy of cinacalcet in Turkish hemodialysis patients. MATERIAL and METHODS: 4483 hemodialysis patients were screened and 469 patients who had used cinacalcet were included in the study. The patients were divided into 4 groups according to drug usage durations (Group 1: 3 months, Group 2: 6 months, Group 3: 9 months and Group 4: 12 months). The patients' Parathormone, Ca, P and CaxP levels at the 3rd, 6th, 9th and 12th months were compared to the start of treatment and previous months. RESULTS: The levels of Parathormone, Ca, P and CaxP significantly decreased compared to their initial levels in all groups (from 1412 pg/ml to 1222 pg/mL for Parathormone, p< 0,001) in the 3rd month. However, this reduction was not continued in the subsequent months (Parathormone: 1381 pg/ml for the 12th month). CONCLUSION: Cinacalcet may not provide adequate benefit in control of hyperparathyroidism in Turkish hemodialysis patient population.en_US
dc.identifier.doi10.5262/tndt.2016.1002.12
dc.identifier.endpage198en_US
dc.identifier.issn1300-7718
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-84969822816en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage192en_US
dc.identifier.urihttps://doi.org/10.5262/tndt.2016.1002.12
dc.identifier.urihttps://hdl.handle.net/20.500.12483/8852
dc.identifier.volume25en_US
dc.identifier.wosWOS:000393291900012en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTurk Nefroloji Diyaliz Transplantasyon Dergisien_US
dc.relation.ispartofTurkish Nephrology Dialysis and Transplantation Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCinacalceten_US
dc.subjectChronic renal failureen_US
dc.subjectHemodialysisen_US
dc.subjectParathormoneen_US
dc.subjectSecondary hyperparathyroidismen_US
dc.titleThe Efficacy of Cinacalcet in the Treatment of Hyperparathyroidism in Turkish Hemodialysis Patient Populationen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
8852.pdf
Boyut:
960.7 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu